Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PTM-101 as an Adjunct to Neoadjuvant Therapy for PDAC
NCT06673017Phase 1Recruiting
- Sponsor
- PanTher Therapeutics
- Start
- Apr 2025
- Primary completion
- Dec 2026
- Countries
- 2
01
Overview
Phase 1, open-label trial of PTM-101 in pancreatic ductal adenocarcinoma (PDAC) (2 arms), sponsored by PanTher Therapeutics. Primary endpoint: Dose-Limiting Toxicities and Safety Profile at 21 days. Started Apr 2025; status: recruiting.
02
Drugs
PTM-101
03
Conditions
pancreatic ductal adenocarcinoma (PDAC)
Beyond the preview
Go deeper on NCT06673017.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06673017.